15 March 2019

ILLUMINA

Illumina is one of the few companies which is at the cutting edge of improving our quality of life

by Michael Bray

Research Analyst

Group 10Created with Sketch.
Price
$321.18
Group 11Created with Sketch.
52 Week High-Low
$372.61—$225.82
Page 1Created with Sketch.
Net Yield
0.0%
Group 12Created with Sketch.
Hist / Pros Per
58.0—49.3
Page 1Created with Sketch.
Equity Market Cap
£47,213

Illumina is one of the few companies which is at the cutting edge of improving our quality of life. It develops highly complex machines which sequence or ‘read’ genomes. Genomes contain our complete set of DNA and include all genes.

By sequencing and deciphering our genomes, it is hoped that we can understand what parts of our DNA make us more susceptible to certain conditions and what treatments will work best to combat them. The end goal being the use of more targeted therapies and better patient outcomes. Many medical breakthroughs have already occurred as a result, particularly in the field of oncology (cancer).

Illumina say just 0.01% of all species have had their DNA sequenced, less than 0.02% of humans have and that 99% of the variants discovered in the genome are not understood. The potential for the business is truly astounding.

But with such exciting prospects comes a hefty valuation, shares trade on 54x last year’s earning, meaning that operational execution will need to be flawless. Additionally, genome sequencing is still a nascent industry which is experiencing rapid technology advancement. Whether Illumina continues to lead it, is not a foregone conclusion


Also in this issue

 You probably don’t know this but the probability that you have a Givaudan product in most of your domestic consumables is very high.Givaudan is based in Switzerland and makes fragrances and flavours.…

You might not know it, but without Cranswick your traditional Sunday morning breakfast might be significantly different to that which you are used to today.In the 1970s the business was formed when a…

Compass haven’t had it easy. December 2017 saw the tragic passing of the impressive CEO, Richard Cousins. This was closely followed by the resignation of long serving CFO, Johnny Thomson and global…